Evolution of treatment targets in IBD has increased the need for objective monitoring of disease activity to guide therapeutic strategy. Although mucosal healing is the current target of therapy in IBD, endoscopy is invasive, expensive and unappealing to patients. GI ultrasound (GIUS) represents a non-invasive modality to assess disease activity in IBD. It is accurate, cost-effective and reproducible. GIUS can be performed at the point of care without specific patient preparation so as to facilitate clinical decision-making. As compared with ileocolonoscopy and other imaging modalities (CT and MRI), GIUS is accurate in diagnosing IBD, detecting complications of disease including fistulae, strictures and abscesses, monitoring disease activity and detecting postoperative disease recurrence. International groups increasingly recognise GIUS as a valuable tool with paradigm-changing application in the management of IBD; however, uptake outside parts of continental Europe has been slow and GIUS is underused in many countries. The aim of this review is to present a pragmatic guide to the positioning of GIUS in IBD clinical practice, providing evidence for use, algorithms for integration into practice, training pathways and a strategic implementation framework.

中文翻译：

---

炎症性肠病中的胃肠超声：一种未充分利用的资源，具有潜在的范式改变应用

IBD 治疗目标的演变增加了对疾病活动的客观监测以指导治疗策略的需求。尽管粘膜愈合是 IBD 的当前治疗目标，但内窥镜检查是侵入性的、昂贵的且对患者没有吸引力。胃肠道超声 (GIUS) 代表了一种评估 IBD 疾病活动的非侵入性方式。它准确、经济且可重复。GIUS 可以在护理点进行，无需特定的患者准备，以促进临床决策。与回肠结肠镜检查和其他影像学检查（CT 和 MRI）相比，GIUS 在诊断 IBD、检测疾病的并发症（包括瘘管、狭窄和脓肿）、监测疾病活动度和检测术后疾病复发方面是准确的。国际组织越来越认识到 GIUS 是一种在 IBD 管理中具有改变范式应用的宝贵工具；然而，欧洲大陆以外部分地区的应用进展缓慢，许多国家未充分利用 GIUS。本综述的目的是为 GIUS 在 IBD 临床实践中的定位提供实用指南，提供使用证据、整合到实践中的算法、培训途径和战略实施框架。